tiprankstipranks
Advertisement
Advertisement

NVS Stock Latest News

Novartis says FDA approves Pluvicto for PSMA+ metastatic prostate cancer
The FlyNovartis says FDA approves Pluvicto for PSMA+ metastatic prostate cancer
3d ago
NVS
SCHD vs. VYMI: Which Dividend ETF Comes Out on Top?
PremiumMarket News
SCHD vs. VYMI: Which Dividend ETF Comes Out on Top?
4d ago
ABT
MRK
Novartis: Solid Fundamentals but Balanced Risk-Reward Justify Hold Rating
PremiumRatings
Novartis: Solid Fundamentals but Balanced Risk-Reward Justify Hold Rating
7d ago
NVS
3 Best Vanguard ETFs to Boost Your Dividend Income
PremiumMarket News
3 Best Vanguard ETFs to Boost Your Dividend Income
7d ago
RY
NVS
Novartis: Balanced Upside Potential and Execution Risks Lead Analyst to Maintain Hold Rating Ahead of Key Phase III Readouts
PremiumRatings
Novartis: Balanced Upside Potential and Execution Risks Lead Analyst to Maintain Hold Rating Ahead of Key Phase III Readouts
7d ago
NVS
Nuvectis’ NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor
PremiumTipRanks NewswireNuvectis’ NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor
11d ago
NVS
CRNX
VYMI vs. SCHD: Which Is the Best Dividend ETF for Passive Income?
Premium
Market News
VYMI vs. SCHD: Which Is the Best Dividend ETF for Passive Income?
11d ago
ABT
MRK
Novartis price target raised to CHF 142 from CHF 132 at Citi
Premium
The Fly
Novartis price target raised to CHF 142 from CHF 132 at Citi
12d ago
NVS
Trump Trade: U.S. to impose 100% tariff on imported generic drugs
PremiumThe Fly
Trump Trade: U.S. to impose 100% tariff on imported generic drugs
12d ago
XE
AAL
Novartis: Sell Rating Maintained as Timing-Driven Upside Keeps Risk‑Reward Unfavorable; $111 Price Target Reaffirmed
PremiumRatings
Novartis: Sell Rating Maintained as Timing-Driven Upside Keeps Risk‑Reward Unfavorable; $111 Price Target Reaffirmed
12d ago
NVS
Novartis: Buy Rating Reiterated on Q2 Beat, Strong Growth Brands and Pipeline Upside; Price Target Maintained at $140
PremiumRatings
Novartis: Buy Rating Reiterated on Q2 Beat, Strong Growth Brands and Pipeline Upside; Price Target Maintained at $140
13d ago
NVS
Novartis Earnings Call Highlights Growth Amid Headwinds
PremiumCompany Announcements
Novartis Earnings Call Highlights Growth Amid Headwinds
13d ago
NVS
Trump to set 100% tariff on generic drugs brought into U.S. starting in 2028
PremiumThe FlyTrump to set 100% tariff on generic drugs brought into U.S. starting in 2028
13d ago
AZN
BMY
Midday Fly By: GM, 3M, Hasbro all post beat and raise reports
Premium
The Fly
Midday Fly By: GM, 3M, Hasbro all post beat and raise reports
13d ago
GM
RL
Morning Movers: Equifax sinks following second quarter earnings
Premium
The Fly
Morning Movers: Equifax sinks following second quarter earnings
13d ago
GM
DHI
Options Volatility and Implied Earnings Moves Today, July 21, 2026
PremiumMarket News
Options Volatility and Implied Earnings Moves Today, July 21, 2026
13d ago
GM
ALK
Novartis Returns to Sales Growth in Q2 2026 but Earnings Weaken as Guidance Reaffirmed
PremiumCompany Announcements
Novartis Returns to Sales Growth in Q2 2026 but Earnings Weaken as Guidance Reaffirmed
13d ago
6K
NVS
Novartis reports Q2 core EPS $2.41 vs. $2.42 last year
PremiumThe Fly
Novartis reports Q2 core EPS $2.41 vs. $2.42 last year
13d ago
NVS
Novartis reaffirms FY26 guidance
PremiumThe Fly
Novartis reaffirms FY26 guidance
13d ago
NVS
Maxim upgrades Akari Therapeutics to Buy on AKTX-101 data, ADC M&A
PremiumThe FlyMaxim upgrades Akari Therapeutics to Buy on AKTX-101 data, ADC M&A
14d ago
NVS
AKTX
The Week That Was, The Week Ahead: Macro and Markets, July 19
Premium
Market News
The Week That Was, The Week Ahead: Macro and Markets, July 19
15d ago
T
BX
NVS Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
NVS Earnings this Week: How Will it Perform?
15d ago
NVS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >